Phase 3 N=330 Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer
Thyroid Cancer
Primary: Progression-Free Survival (PFS) — 11.2; 4.0 months
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=21 Sorafenib Tosylate in Treating Patients With Metastatic, Locally Advanced, or Recurrent Medullary Thyroid Cancer
Hereditary Thyroid Gland Medullary Carcinoma · Locally Advanced Thyroid Gland Medullary Carcinoma · Multiple Endocrine Neoplasia Type 2A
Primary: Objective Response Rate of Sorafenib Tosylate in Metastatic Medullary Thyroid Carcinoma in Setting of Inherited Tumor Syndromes as Well as in Setting of Sporadic…
Phase 2 N=17 Pembrolizumab in Recurrent or Metastatic Medullary Thyroid Cancer
Medullary Thyroid Cancer (MTC)
Primary: Clinical Response — 0; 0 Participants
Phase 2 N=19 A Study To Assess ZD6474 (ZACTIMA™) Monotherapy In Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer
Thyroid Cancer
Primary: Objective Response Rate (ORR) — 3 Participants
Phase 2 N=14 Evaluate the Safety and Tolerability of Vandetanib in Japanese Patients With Medullary Thyroid Carcinoma
Unresectable Locally Advanced or Metastatic, Medullary Thyroid Carcinoma
Primary: Objective Response Rate Within the First 56 Weeks After the First Dose of Vandetanib — 38.5 percentage of participants
Phase 2 N=30 Efficacy and Tolerability of ZD6474 in Patients With Thyroid Cancer
Thyroid Cancer
Primary: Objective Response Rate — 6 Participants
Phase 3 N=417 Nexavar® Versus Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer
Thyroid Neoplasms
Primary: Progression-free Survival (PFS) Based on Central Assessment Incl. Clinical Progression Due to Bone Irradiation — 329; 175 Days — p=<0.0001
Phase 2 N=3 A Phase I/II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer and Incurably Poorly Differentiated or Radioidodine Refractory Differentiated Thyroid Cancer
Anaplastic Thyroid Cancer · Thyroid Cancer · Differentiated Thyroid Cancer
Primary: Maximum Tolerated Dose (MTD) [Phase I Dose Escalation] — 5 mg
Phase 2 N=9 Abemaciclib in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer
Thyroid Cancer · Anaplastic Thyroid Cancer · Undifferentiated Thyroid Cancer
Primary: Number of Participants With Overall Response (OR) — 0 Participants
Phase 2 N=117 Evaluating the Safety and Efficacy of Oral Lenvatinib in Medullary and Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers, Stratified by Histology
Thyroid Cancer
Primary: Objective Response Rate (ORR) — 50.0; 35.6 Percentage of participants
Phase 2 N=50 RAD001 for Patients With Radioiodine Refractory Thyroid Cancer
Thyroid Cancer
Primary: Median Progression Free Survival — 12.5 months
Phase 2 N=13 Trial of LBH589 in Metastatic Thyroid Cancer
Thyroid Carcinoma
Primary: Tumor Response Rate to LBH589. — 13; 0 participants
Phase 2 N=42 Pasireotide & Everolimus in Adult Patients With Radioiodine-Refractory Differentiated & Medullary Thyroid Cancer
Thyroid Cancer
Primary: Number of Participants With Response Per Responsive Evaluation Criteria in Solid Tumors Criteria (RECIST v1.0) — 17; 9; 11 Participants
Phase 2 N=25 Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer
Poorly Differentiated Thyroid Gland Carcinoma · Recurrent Thyroid Gland Carcinoma · Stage I Thyroid Gland Follicular Carcinoma
Primary: Objective Response Rate, Defined as the Proportion of Patients Who Have Had a PR or CR as Assessed by the RECIST Version (v)1.1 — 10 Participants
Phase 2 N=17 Vandetanib to Treat Children and Adolescents With Medullary Thyroid Cancer
Medullary Thyroid Carcinoma · Multiple Endocrine Neoplasia Type 2A · Multiple Endocrine Neoplasia Type 2B
Primary: Maximum Tolerated Dose (MTD) — 100 mg/m^2/day
Phase 2 N=18 Cabozantinib in Treating Patients With Locally Advanced or Metastatic Unresectable Adrenocortical Carcinoma
Metastatic Carcinoma in the Adrenal Cortex · Stage III Adrenal Cortex Carcinoma AJCC v8 · Stage IV Adrenal Cortex Carcinoma AJCC v8
Primary: Progression-free Survival (PFS) as Defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 Criteria — 72.2 precentage of participants
Phase 3 N=331 An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer
Thyroid Cancer
Primary: Progression-Free Survival(PFS) — 30.5; 19.2 Months
Phase 2 N=41 Aflibercept in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy
Recurrent Thyroid Gland Carcinoma · Stage III Thyroid Gland Follicular Carcinoma · Stage III Thyroid Gland Papillary Carcinoma
Primary: Progression-free Survival to Determine the 6-month Progression-free-survival (PFS) Rate — 5.4 months
Phase 2 N=35 Sunitinib Malate in Treating Patients With Iodine-Refractory Recurrent or Metastatic Thyroid Cancer
Recurrent Thyroid Cancer · Stage IVA Follicular Thyroid Cancer · Stage IVA Papillary Thyroid Cancer
Primary: Overall Response Rate — 11 Participants
Phase 2 N=41 Tanespimycin in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid Cancer
Recurrent Thyroid Cancer · Stage IV Follicular Thyroid Cancer · Stage IV Papillary Thyroid Cancer
Primary: Proportion of Patients Who Have Remained on Treatment and Progression-free at Least One Year After Start of 17-AAG (Tanespimycin) — 5.9; 12.5 percentage of participants
Phase 2 N=6 Pembrolizumab in Anaplastic/Undifferentiated Thyroid Cancer
Anaplastic Thyroid Cancer
Primary: Overall Response (OR) — 0; 3; 3; 1 Participants
Phase 2 N=23 Sutent Adjunctive Treatment of Differentiated Thyroid Cancer
Papillary Thyroid Cancer · Follicular Thyroid Cancer · Differentiated Thyroid Cancer
Primary: Progression Free Survival — 241 days
Phase 2 N=590 Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors
RET-altered Non Small Cell Lung Cancer · Medullary Thyroid Cancer · RET-altered Papillary Thyroid Cancer
Primary: Phase 1 : Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of Pralsetinib — 400; 400 mg
Phase 2 N=145 Efficacy and Safety of Vandetanib (ZD6474) in Patients With Metastatic Papillary or Follicular Thyroid Cancer
Thyroid Neoplasms
Primary: Time to Tumor Progression — 334; 176 days
Phase 4 N=81 To Compare The Effects Of Two Doses Of Vandetanib In Patients With Advanced Medullary Thyroid Cancer
Thyroid Cancer
Primary: Overall Response Rate (ORR) for Vandetanib 150 and 300mg With Responses Determined by the Investigator — 0.20; 0.29 Proportion of participants
Phase 2 N=51 A Study of Vemurafenib (RO5185426) in Participants With Metastatic or Unresectable Papillary Thyroid Cancer Positive for the BRAF V600 Mutation
Neoplasms
Primary: Best Overall Response Rate in TKI-Naive Participants — 42.3 percentage of participants
Phase 2 N=19 Suberoylanilide Hydroxamic Acid in Treating Patients With Metastatic and/or Locally Advanced or Locally Recurrent Thyroid Cancer
Insular Thyroid Cancer · Recurrent Thyroid Cancer · Stage II Follicular Thyroid Cancer
Primary: Objective Response Rate (PR + CR) Using RECIST/WHO Response Criteria — 0; 0; 0; 0 percentage of participants
Phase 2 N=35 QUILT-3.006 for Recurrent Medullary Thyroid Cancer
Medullary Thyroid Cancer (MTC)
Primary: Calcitonin Growth Rate — -2.53; -2.49 days^-1 — p=0.3760
Phase 3 N=238 Evaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid Cancer
Differentiated Thyroid Cancer
Primary: Progression-Free Survival (PFS) — 10.0; 5.7 months — p=0.080
Phase 2 N=53 Dabrafenib With or Without Trametinib in Treating Patients With Advanced Differentiated Thyroid Cancer
Follicular Thyroid Cancer · Insular Thyroid Cancer · Papillary Thyroid Cancer
Primary: Overall Objective Response Rate, Defined as the Proportion of Patients Who Have a Minor Response (MR), Partial Response (PR), or Complete Response(CR)Assessed According…